Odyssey Therapeutics (ODTX) news
Recent news
Odyssey Therapeutics reports first quarter 2026 financial results and provides corporate update
AInvest Wire · Jun 17, 2026Odyssey raises $310M in Series B at $1.45B valuation
Odyssey Therapeutics, a biotechnology company focused on developing precision immunomodulators and oncology medicines, has raised $310 million in its Series B financing round at a valuation of $1.45 billion. The funding, which includes both new and existing investors, follows the company’s $218…
AInvest Wire · Jun 17, 2026Odyssey raises $310M to accelerate world simulation
On June 17, 2026, Odyssey, an artificial intelligence startup, announced it has raised $310 million in funding to advance its development of world simulation technologies. The investment, led by Amazon, underscores interest in AI systems capable of modeling and simulating real-world environments.…
AInvest Wire · Jun 17, 2026Odyssey Therapeutics Inc <ODTX.O>: TD Cowen initiates coverage with buy rating
Odyssey Therapeutics Inc : TD Cowen initiates coverage with buy rating : TD Cowen initiates coverage with buy rating">
AInvest Wire · Jun 2, 2026S&P downgrades Odyssey Logistics to 'CCC+'; outlook negative
Odyssey Logistics has been downgraded by S&P Global Ratings to 'CCC+' with a negative outlook, reflecting heightened credit risk and ongoing challenges in the freight market. This follows a similar downgrade by Moody’s earlier in the year, which cut Odyssey’s rating to Caa1 from B3. S&P’s…
AInvest Wire · May 22, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.